CMR Naviscan

CMR Naviscan, a unit of the larger CMR corporation, is a commercial-stage medical device company specializing in molecular breast imaging. Its core product, the LumaGEM MBI system, addresses a critical gap in breast cancer screening for the approximately 40-50% of women with dense breast tissue, where mammography is less effective. The company's value proposition is built on clinical data showing increased invasive cancer detection rates and a reduction in unnecessary biopsies, leading to proven healthcare savings. Operating as a private entity, it leverages over 40 years of parent company expertise in diagnostic imaging to market its FDA-registered systems.

Gamma camera-based Molecular Breast Imaging (MBI) utilizing a radioactive tracer (Tc-99m sestamibi) to detect metabolic activity of breast cancer cells, with high-resolution imaging capabilities.

Competes directly with breast MRI (higher cost, superior sensitivity but lower accessibility) and supplemental ultrasound (lower cost but higher false-positive rates). Also faces emerging competition from contrast-enhanced spectral mammography and advanced AI applications for standard mammography.